Detail akcie Omeros online

Business Summary: Omeros Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan diseases, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The Company's lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before the FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. Its lead phosphodiesterase 7 (PDE7) inhibitor, OMS527, is in clinical development for the treatment of cocaine use disorders. The Company also has preclinical programs, including an oncology platform for the development of novel therapeutics.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Omeros Corp revenues was not reported. Net loss before extraordinary items decreased 97% to $4.8M. Lower net loss reflects Biopharmaceutical company segment loss decrease of 27% to $122.8M. Basic Earnings per Share excluding Extraordinary Items increased from -$3.14 to -$0.08.